Abstract: A sheet of aluminum is formed to a mold by applying gas pressure. Thermoplastic resin is heated and applied to the aluminum in a selected pattern through a nozzle. In one embodiment, the thermoplastic resin is applied to the aluminum sheet in a hexagonal pattern that transitions to a columnar pattern. In a further embodiment microballons or micro-spheres are added to the heated thermoplastic resin to reduce viscosity. A backing layer of aluminum sheet is formed to the patterned resin composite. Gas forming of the aluminum sheet results in aspect ratios of up to 0.6, and the sheet maintains a clean surface that directly bonds to the applied resin.

Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, atorvastatin, and derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis or they are the products of total chemical synthesis. The aforementioned active substances may be destabilized by the environmental factors, their degradation may also be accelerated by interactions with other pharmaceutical ingredients, such as fillers, binders, lubricants, glidants and disintegrating agents, therefore the pharmaceutical ingredients and the process for preparation of the pharmaceutical formulation should be meticulously chosen to avoid the aforementioned undesired interactions and reactions.

Abstract: A liquid aqueous pharmaceutical suspension formulation containing as amoxycillin trihydrate, potassium clavulanate and microcrystalline cellulose filler is provided.

Abstract: This invention relates to a novel method for the removal of a silyl protecting group from the 4-hydroxy group of tetrahydropyran-2-ones, which method is particularly suitable in the process for the preparation of simvastatin and derivatives and analogs thereof.

Abstract: Disclosed are novel ethylidene derivatives of tricyclic carbapenems of the formula I wherein the ring marked C and X have the meaning as in the description, in the form of pure diastereoisomers and in the form of pure geometric isomers. Novel ethylidene derivatives of tricyclic carbapenems of the formula I are used as inhibitors of the action of the enzyme &bgr;-lactamase and/or as antibiotics in human and veterinary medicine. Also disclosed are pharmaceutical formulations for the treatment of bacterial infections of human and animal organisms comprising as an active ingredient a therapeutically effective amount of an ethylidene derivative of tricyclic carbapenems of the formula I in the form of an acid, a pharmaceutically acceptable salt or ester thereof and optionally in a combination with a &bgr;-lactam antibiotic, and usual pharmaceutically acceptable carriers and auxiliary substances.

Abstract: Lovastatin, pravastatin, simvastatin, mevastatin, derivatives and analogs thereof are known as HMG-CoA reductase inhibitors and are used as antihypercholesterolemic agents. The majority of them are produced by fermentation using microorganisms of different species identified as species belonging to Aspergillus, Monascus, Nocardia, Amycolatopsis, Mucor or Penicillium genus, and some are obtained by treating the fermentation products using the methods of chemical synthesis for example simvastatin. This invention relates to the novel method for the acylation of sterically hindered alcohols which is applicable in the process for the preparation of simvastatin and derivatives thereof.

Abstract: Provided is a process for purification of clavulanic acid or a pharmaceutically acceptable salt or ester thereof, including adding an additional solvent to a solution of clavulanic acid in water immiscible solvent; contacting the solution with an amine; isolating the amine salt of the clavulanic acid formed; and converting the amine into clavulanic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: The very effective conversion of ML-236B substances and derivatives thereof into 6′-hydroxylated products with the microorganisms of species Amycolatopsis orientalis, or with an extract or a hydroxylation-effective enzyme derived from said microorganism, is described. The products obtained are suitable as HMG-CoA reductase inhibitors or intermediates thereof. Thus, the products can be used, for example, as an antihypercholesterolemic in pharmacy.

Abstract: A surface structure including a skin (13) a build-up (18) and a backing (20). A skin is formed and a build-up layer is applied to the skin. In one embodiment, gas pressure is applied to form the skin in a single-sided die. A nozzle on a five-axis arm then applies resin to the skin in a selected pattern. The selected pattern may form a hexagonal “honeycomb” cell structure, for example, to support the skin and may transition to a columnar cell structure for better crush resistance. The hexagonal-to-columnar structure provides superior crush resistance in automotive body panels, for example, and improved solar energy concentration in solar energy applications.

Abstract: An apparatus for forming a surface structure. The apparatus forms a skin to a single-sided die by applying gas pressure to a skin preform placed between the die and a cap that confines the gas against the skin preform. The apparatus also has a dispensing apparatus that is movable in relation to the surface of the skin/die. In one embodiment the dispensing apparatus is a heated nozzle on a crane arm that has five axis of movement with respect to the surface of the die. The nozzle dispenses fluid plastic, for example, in a selected pattern and at a selected height on the skin.

Abstract: ? Provided is a process for purification of clavulanic acid or a pharmaceutically acceptable salt or ester thereof, including adding an additional solvent to a solution of clavulanic acid in water immiscible solvent; contacting the solution with an amine; isolating the amine salt of the clavulanic acid formed; and converting the amine into clavulanic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: Provided is a process for preparation and/or purification of clavulanic acid or a pharmaceutically acceptable salt or ester thereof including removing solids from a clavulanic acid containing fermentation broth by microfiltration to form a first filtrate, further removing solids from the first filtrate by ultrafiltration to form a second filtrate, concentrating the second filtrate by removal of water, and treating the concentrated second filtrate to isolate clavulanic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: An improved process of synthesis of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl-1H-benzimidazole (omeprazole) by oxidation of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio]benzimidazole with 3-chloroperoxy-benzoic acid in ethyl acetate wherein omeprazole is poorly soluble, at a temperature between −10° C. and 5° C. is disclosed. The second step is a purification of the crude product by dissolution and reprecipitation of the final product.

Abstract: An aluminum-thermoplastic composite surface structure. A sheet of aluminum is formed to a single-sided mold by heating the sheet and applying a ramp of gas pressure. A thermoplastic resin is heated and microballons are added to the resin to lower the viscosity of the resin, which is applied through a nozzle in a hexagonal pattern on the formed aluminum sheet. Upon cooling, the composite resin forms a honeycomb pattern. The hexagonal pattern transitions to a columnar pattern, and a backing layer of aluminum sheet is gas pressure formed to the resin composite. Gas forming of the aluminum sheet results in aspect ratios of up to 0.6, and the sheet maintains a clean surface that bonds to the applied resin.

Abstract: A process for the isolation of clavulanic acid and pharmaceutically acceptable salts thereof, such as potassium clavulanate, from the aqueous fermentation broth of a clavulanic acid-producing microorganism comprises the microfiltration of the broth without prior treatment.

Abstract: Provided is a process for purification of clavulanic acid or a pharmaceutically acceptable salt or ester thereof, including adding an additional solvent to a solution of clavulanic acid in water immiscible solvent; contacting the solution with an amine; isolating the amine salt of the clavulanic acid formed; and converting the amine into clavulanic acid or a pharmaceutically acceptable salt or ester thereof.

Abstract: An apparatus for forming a surface structure. In one embodiment, the apparatus has three stations, with a single-sided mold, or die, at each station. A skin is formed to a single-sided die at the first station, by applying gas pressure to a skin preform placed between the die and a cap that confines the gas against the skin preform, for example. The die and skin are then rotated to a second station where a build-up is applied to the skin, and then rotated to a third station where a backing is applied to the build-up to result in a unitary surface structure.

Abstract: Described is a novel three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient stabilized with polymers for a single daily peroral application, which is especially suitable for active ingredients existing in amorphous form or in one or more polymorphous forms, which exhibit poor solubility in crystal form depending on the polymorphous form, particle size and the specific surface area of the active ingredient. The active ingredient can be used in its amorphous or any polymorphous form, which in the process of the preparation of the three-phase pharmaceutical form according to the invention is converted into the amorphous form. The three-phase pharmaceutical form with constant and controlled release of an amorphous active ingredient for a single daily peroral application contains a core consisting of a first and a second phase and a coating representing the third phase.

Abstract: Provided is a process for preparation of pharmaceutically acceptable metal salts of clavulanic acid which avoids the use of toxic amines or other intermediates. The process involves removing solids from a clavulanic acid containing fermentation broth by microfiltration; acidifying the microfiltrate to a pH of between 1 and 3; extracting the acidified microfiltrate with a water immiscible solvent and separating the clavulanic acid containing extract; without converting the clavulanic acid containing extract to an intermediate clavulanate salt, mixing the extract with a metal donor and at least one additional non-aqueous solvent; and separating a pharmaceutically acceptable metal clavulanate salt from the solution.

Abstract: A process for the isolation of clavulanic acid pharmaceutically acceptable salts thereof, such as potassium clavulanate, from the aqueous fermentation broth of a clavulanic acid-producing microogranism comprises the microfiltration of the broth without prior treatment.